Vimta Labs Limited - Asset Resilience Ratio
Vimta Labs Limited (VIMTALABS) has an Asset Resilience Ratio of 0.36% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See VIMTALABS net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2026)
This chart shows how Vimta Labs Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see VIMTALABS total asset value.
Liquid Assets Composition Over Time
This chart breaks down Vimta Labs Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read VIMTALABS total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs19.98 Million | 0.36% |
| Total Liquid Assets | Rs19.98 Million | 0.36% |
Asset Resilience Insights
- Limited Liquidity: Vimta Labs Limited maintains only 0.36% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Vimta Labs Limited Industry Peers by Asset Resilience Ratio
Compare Vimta Labs Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 13.87% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Bionet
TWO:1784 |
Diagnostics & Research | 41.08% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for Vimta Labs Limited (2006–2026)
The table below shows the annual Asset Resilience Ratio data for Vimta Labs Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 0.36% | Rs19.98 Million ≈ $216.08K |
Rs5.62 Billion ≈ $60.80 Million |
-3.26pp |
| 2025-03-31 | 3.62% | Rs168.85 Million ≈ $1.83 Million |
Rs4.67 Billion ≈ $50.45 Million |
+0.58pp |
| 2024-03-31 | 3.04% | Rs121.60 Million ≈ $1.32 Million |
Rs4.00 Billion ≈ $43.26 Million |
+0.54pp |
| 2023-03-31 | 2.50% | Rs90.73 Million ≈ $981.21K |
Rs3.62 Billion ≈ $39.18 Million |
+2.37pp |
| 2022-03-31 | 0.13% | Rs4.06 Million ≈ $43.91K |
Rs3.07 Billion ≈ $33.22 Million |
-0.01pp |
| 2021-03-31 | 0.14% | Rs3.92 Million ≈ $42.39K |
Rs2.74 Billion ≈ $29.67 Million |
-0.24pp |
| 2020-03-31 | 0.38% | Rs9.32 Million ≈ $100.79K |
Rs2.46 Billion ≈ $26.58 Million |
+0.18pp |
| 2019-03-31 | 0.20% | Rs4.70 Million ≈ $50.83K |
Rs2.37 Billion ≈ $25.68 Million |
-0.85pp |
| 2018-03-31 | 1.05% | Rs24.39 Million ≈ $263.77K |
Rs2.32 Billion ≈ $25.12 Million |
+0.58pp |
| 2017-03-31 | 0.47% | Rs10.45 Million ≈ $113.01K |
Rs2.22 Billion ≈ $23.97 Million |
+0.38pp |
| 2011-03-31 | 0.09% | Rs1.58 Million ≈ $17.09K |
Rs1.77 Billion ≈ $19.09 Million |
-12.57pp |
| 2007-03-31 | 12.66% | Rs220.22 Million ≈ $2.38 Million |
Rs1.74 Billion ≈ $18.81 Million |
-28.47pp |
| 2006-03-31 | 41.13% | Rs702.53 Million ≈ $7.60 Million |
Rs1.71 Billion ≈ $18.47 Million |
-- |
About Vimta Labs Limited
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract researc… Read more